CJC-1295 No DAC

In laboratory research environments, CJC-1295 (No DAC) is commonly investigated in studies involving:

• Growth hormone signaling pathway research• Pituitary receptor pharmacology• Endocrine regulatory pathway modeling• Peptide-mediated hormonal communication research• Hypothalamic–pituitary axis signaling investigation

These research areas make CJC-1295 (No DAC) a valuable compound for laboratories studying growth hormone axis biology and peptide-mediated endocrine regulatory systems.

CJC-1295 (No DAC), often referred to as Modified Growth Hormone–Releasing Factor 1-29 (Mod GRF 1-29), is a synthetic peptide analog derived from the first 29 amino acids of growth hormone–releasing hormone (GHRH). This portion of the GHRH molecule represents the biologically active region responsible for interacting with growth hormone–releasing hormone receptors located in the anterior pituitary gland.

Through structural modifications, the peptide has been engineered to provide improved stability and resistance to enzymatic degradation compared to the naturally occurring hormone fragment. Because of these characteristics, CJC-1295 (No DAC) has become an area of interest in scientific research examining growth hormone axis signaling and peptide-mediated endocrine communication pathways.

Unlike the version containing a Drug Affinity Complex (DAC), CJC-1295 without DAC does not bind to circulating albumin. This distinction allows researchers to study the peptide in laboratory models investigating shorter-duration receptor signaling interactions within endocrine regulatory systems.

Compound Name: CJC-1295 (No DAC) / Mod GRF 1-29
Format: Lyophilized peptide powder
Purity: ≥99% (HPLC verified)
Verification: Mass spectrometry confirmed
Storage: Store in a cool, dry environment. Refrigeration recommended for long-term stability.

CJC-1295 (No DAC) is studied for its interaction with growth hormone–releasing hormone receptors (GHRH receptors) located within the anterior pituitary gland.

Scientific literature frequently examines this peptide in relation to:

• Growth hormone–releasing hormone receptor signaling• Hypothalamic–pituitary endocrine communication pathways• Peptide-mediated hormonal regulatory mechanisms• Growth hormone axis signaling dynamics• Endocrine peptide signaling pathway research

These pathways are important areas of investigation in research exploring growth hormone regulatory systems and peptide-driven endocrine signaling networks.